A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice

Hugues Fausther-Bovendo, Marie Eve Hamelin, Julie Carbonneau, Marie Christine Venable, Liva Checkmahomed, Pierre Olivier Lavoie, Marie Ève Ouellet, Guy Boivin, Marc André D’Aoust, Gary P. Kobinger

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Human metapneumovirus (HMPV) and human respiratory virus (HRSV) are two leading causes of acute respiratory tract infection in young children. While there is no licensed drug against HMPV, the monoclonal antibody (mAb) Palivizumab is approved against HRSV for prophylaxis use only. Novel therapeutics against both viruses are therefore needed. Here, we describe the identification of human mAbs targeting these viruses by using flow cytometry-based cell sorting. One hundred and two antibodies were initially identified from flow cytometry-based cell sorting as binding to the fusion protein from HRSV, HMPV or both. Of those, 95 were successfully produced in plants, purified and characterized for binding activity by ELISA and neutralization assays as well as by inhibition of virus replication in mice. Twenty-two highly reactive mAbs targeting either HRSV or HMPV were isolated. Of these, three mAbs inhibited replication in vivo of a single virus while one mAb could reduce both HRSV and HMPV titers in the lung. Overall, this study identifies several human mAbs with virus-specific therapeutic potential and a unique mAb with inhibitory activities against both HRSV and HMPV.

Original languageEnglish (US)
Article number2516
Issue number10
StatePublished - Oct 2022


  • HMPV
  • HRSV
  • therapeutic antibodies

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice'. Together they form a unique fingerprint.

Cite this